Ovarian Cancer | Specialty

The OncLive Ovarian Cancer condition center page is a comprehensive resource for clinical news and expert insights on ovarian cancer and evolving treatment approaches, including PARP inhibitors, antibody-drug conjugates, chemotherapy and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in ovarian cancer.

Novel CDH6-Targeted ADC DS-6000 Enters the Pipeline in RCC and Ovarian Cancer

February 23rd 2021

February 23, 2021 - The first patient in a first-in-human phase 1 study has been dosed with DS-6000, a novel CDH6-directed antibody-drug conjugate.

FDA Grants Fast Track Status to Immunotherapy GEN-1 in Advanced Ovarian Cancer

February 22nd 2021

February 22, 2021 - The FDA has granted a fast track designation to the DNA-mediated interleukin-12 immunotherapy GEN-1 for use in the treatment of patients with advanced ovarian cancer.

Germline Genetic Testing Gap Persists in Ovarian Cancer, More Delimited Panel Composition Needed to Improve Utility

February 16th 2021

February 16, 2021 - Only 34.3% of 14,689 patients with ovarian cancer received germline genetic testing between 2013 and 2019, revealing persistent underuse of testing among this population.

Dr. Chern on Opportunities for PARP Combinations in Recurrent Ovarian Cancer

February 16th 2021

Jing-Yi Chern, MD, ScM, discusses efforts being made to combine PARP inhibitors with chemotherapy and immunotherapy in patients with recurrent ovarian cancer.

Dr. Brown on Future Directions for Surgery in Ovarian Cancer

February 5th 2021

Jubilee Brown, MD, discusses future directions for surgery in ovarian cancer.

Dr. Cohen on the Efficacy of PARP Inhibitors in Ovarian Cancer

February 5th 2021

Joshua G. Cohen, MD, FACOG, FACS, discusses the efficacy of PARP inhibitors in patients with ovarian cancer.

Dr. Markman on the Need for Comparative Trials With PARP Inhibitors in Ovarian Cancer

February 3rd 2021

Maurie Markman, MD, discusses the need for comparative clinical trials with PARP inhibitors in ovarian cancer.

PFS Deserves More Than Surrogate Status as a Clinical Trial End Point

January 20th 2021

Although recent benefits do not pertain to all cancers and “cure” remains a relatively uncommon event, oncologists have an increasing number of molecularly targeted and immunotherapeutic strategies to employ based on objectively meaningful clinical trial outcomes.

Dr. Lees on the Utility of Genetic Testing in Ovarian Cancer

January 14th 2021

Brittany F. Lees, MD, discusses the utility of genetic and genomic testing in ovarian cancer.

Dr. Konecny on the Survival Benefit Achieved With Maintenance PARP Inhibitors in Ovarian Cancer

January 14th 2021

Gottfried E. Konecny, MD, discusses the impact of maintenance PARP inhibitors on survival in patients with ovarian cancer.

Dr. Zakhour on Clinical Trials Examining Frontline Maintenance PARP Inhibitors in Ovarian Cancer

January 14th 2021

Mae Zakhour, MD, discusses clinical trials that evaluated frontline maintenance PARP inhibitors in patients with ovarian cancer.

Dr. Naumann on the TOPACIO Trial With Pembrolizumab/Niraparib in Ovarian Cancer

January 12th 2021

R. Wendel Naumann, MD, discusses the significance of the phase 1/2 TOPACIO trial in ovarian cancer.

Dr. Puechl on Choosing Between PARP Inhibitors in Ovarian Cancer

January 11th 2021

Allison M. Puechl, MD, discusses choosing between PARP inhibitors in ovarian cancer.

Questions Remain Regarding PARP Inhibition in Recurrent Platinum-Sensitive Ovarian Cancer

January 11th 2021

Joshua G. Cohen, MD, FACOG, FACS, discusses the efficacy of PARP inhibitors in ovarian cancer, remaining questions regarding repeat inhibition and treatment duration, and the potential for combinations.

Dr. Crane on the Benefit of Maintenance PARP Inhibitors in Ovarian Cancer

January 8th 2021

Erin K. Crane, MD, MPH, discusses the benefit of maintenance PARP inhibitors in ovarian cancer.

Dr. Brown on the Utility of Minimally Invasive Surgery in Ovarian Cancer

January 8th 2021

Jubilee Brown, MD, discusses the utility of minimally invasive surgery in ovarian cancer.

RAF/MEK Inhibitor VS-6766 Plus Defactinib Under Exploration in Recurrent Low-Grade Serous Ovarian Cancer

January 6th 2021

January 6, 2021 — The oral small molecule inhibitor VS-6766, developed by Verastem Oncology, is now under investigation alone and in combination with the FAK inhibitor defactinib in a recently initiated, registration-directed, phase 2 trial in patients with recurrent low-grade serous ovarian cancer.

Boehringer Ingelheim Looks to Expand Targeted Therapies Portfolio

January 5th 2021

January 5, 2020 - Boehringer Ingelheim will add to its cancer cell-directed therapies portfolio with the acquisition of NBE-Therapeutics, the developer of NBE-002, an anti-ROR1 antibody-drug conjugate.

Rucaparib Significantly Improves PFS Over Chemo in Later-Line, BRCA+ Ovarian Cancer

December 21st 2020

December 21, 2020 - Rucaparib was found to result in a statistically significant improvement in progression-free survival compared with chemotherapy in patients with BRCA-mutant ovarian cancer who had previously received 2 or more lines of chemotherapy.

Weighing Risks and Benefits Is Critical With Second-Line Maintenance PARP Inhibition in Ovarian Cancer

December 19th 2020

Allison M. Puechl, MD, discusses the role of second-line maintenance therapy in patients with recurrent ovarian cancer and considerations that may limit the accessibility of PARP inhibitors in this space.